
Nigel Stallard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1331929/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. New England Journal of Medicine, 2018, 379, 711-721.	27.0	495
2	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 546.	7.4	229
3	Optimal Adaptive Designs for Binary Response Trials. Biometrics, 2001, 57, 909-913.	1.4	207
4	The changing face of cardiovascular disease 2000–2012: An analysis of the world health organisation global health estimates data. International Journal of Cardiology, 2016, 224, 256-264.	1.7	197
5	Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine, 2003, 22, 689-703.	1.6	171
6	Effectiveness of a Web-Based Cognitive-Behavioral Tool to Improve Mental Well-Being in the General Population: Randomized Controlled Trial. Journal of Medical Internet Research, 2012, 15, e2.	4.3	142
7	HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial. PLoS Medicine, 2019, 16, e1002719.	8.4	131
8	Socioeconomic risk, parenting during the preschool years and child health age 6 years. European Journal of Public Health, 2007, 17, 508-513.	0.3	119
9	Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. Journal of Biopharmaceutical Statistics, 2016, 26, 99-119.	0.8	93
10	A groupâ€sequential design for clinical trials with treatment selection. Statistics in Medicine, 2008, 27, 6209-6227.	1.6	90
11	DELTA ² guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ: British Medical Journal, 2018, 363, k3750.	2.3	90
12	A confirmatory seamless phase II/III clinical trial design incorporating shortâ€ŧerm endpoint information. Statistics in Medicine, 2010, 29, 959-971.	1.6	84
13	Optimal sample sizes for phase II clinical trials and pilot studies. Statistics in Medicine, 2012, 31, 1031-1042.	1.6	84
14	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.2	81
15	A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine, 2012, 31, 4309-4320.	1.6	80
16	Improving the Efficiency of Advanced Life Support Training. Annals of Internal Medicine, 2012, 157, 19.	3.9	79
17	An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several. Journal of Biopharmaceutical Statistics, 2005, 15, 641-658.	0.8	77
18	Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory. Biometrics, 1998, 54, 279.	1.4	73

#	Article	IF	CITATIONS
19	A newly devised scoring system for prediction of mortality in patients with colorectal cancer: a prospective study. Lancet Oncology, The, 2007, 8, 317-322.	10.7	69
20	Reduction in the rate of methicillin-resistant Staphylococcus aureus acquisition in surgical wards by rapid screening for colonization: a prospective, cross-over study. Clinical Microbiology and Infection, 2010, 16, 333-339.	6.0	68
21	Recommendations for the design of small population clinical trials. Orphanet Journal of Rare Diseases, 2018, 13, 195.	2.7	68
22	Bayesian Graphical Models for Genomewide Association Studies. American Journal of Human Genetics, 2006, 79, 100-112.	6.2	63
23	Parenting and health in mid-childhood: a longitudinal study. European Journal of Public Health, 2008, 18, 300-305.	0.3	63
24	Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes. Biometrics, 1999, 55, 971-977.	1.4	59
25	Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine, 2011, 30, 1528-1540.	1.6	57
26	The System-Wide Effect of Real-Time Audiovisual Feedback and Postevent Debriefing for In-Hospital Cardiac Arrest. Critical Care Medicine, 2015, 43, 2321-2331.	0.9	56
27	Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection. Journal of Biopharmaceutical Statistics, 2014, 24, 168-187.	0.8	55
28	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 2016, 20, 1-202.	2.8	53
29	Subacromial balloon spacer for irreparable rotator cuff tears of the shoulder (START:REACTS): a group-sequential, double-blind, multicentre randomised controlled trial. Lancet, The, 2022, 399, 1954-1963.	13.7	53
30	Seamless phase II/III designs. Statistical Methods in Medical Research, 2011, 20, 623-634.	1.5	52
31	A Comparison of Methods for Adaptive Treatment Selection. Biometrical Journal, 2008, 50, 767-781.	1.0	51
32	A systematic literature review of the risk factors associated with children entering public care. Child: Care, Health and Development, 2013, 39, 628-642.	1.7	50
33	DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. Trials, 2018, 19, 606.	1.6	50
34	Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference, 2005, 135, 402-419.	0.6	49
35	Should randomised controlled trials be the "gold standard―for research on preventive interventions for children?. Journal of Children's Services, 2011, 6, 228-235.	0.7	49
36	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology, 2019, 106, 108-120.	5.0	49

#	Article	IF	CITATIONS
37	A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 81-88.	3.0	46
38	Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): Trial protocol. Resuscitation, 2016, 108, 75-81.	3.0	43
39	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	1.9	43
40	Association of maternal vitamin B12 and folate levels in early pregnancy with gestational diabetes: a prospective UK cohort study (PRiDE study). Diabetologia, 2021, 64, 2170-2182.	6.3	42
41	Emergency nurse practitioners and doctors consulting with patients in an emergency department: a comparison of communication skills and satisfaction. Emergency Medicine Journal, 2009, 26, 400-404.	1.0	41
42	Doseâ€finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal, 2017, 59, 804-825.	1.0	41
43	A Practical Comparison of Group-Sequential and Adaptive Designs. Journal of Biopharmaceutical Statistics, 2005, 15, 719-738.	0.8	40
44	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 483-497.	0.8	40
45	Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference, 2008, 138, 1629-1638.	0.6	37
46	Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. Clinical Oncology, 2013, 25, 109-116.	1.4	37
47	Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics, 2005, 4, 119-128.	1.3	36
48	Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Statistics in Medicine, 2013, 32, 2893-2910.	1.6	36
49	Stopping rules for phase II studies. British Journal of Clinical Pharmacology, 2001, 51, 523-529.	2.4	35
50	Interim analyses and sequential designs in phase III studies. British Journal of Clinical Pharmacology, 2001, 51, 394-399.	2.4	34
51	On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Annals of Oncology, 2019, 30, 506-509.	1.2	34
52	Repeated measures proportional odds logistic regression analysis of ordinal score data in the statistical software package R. Computational Statistics and Data Analysis, 2009, 53, 632-641.	1.2	33
53	Effectiveness and cost-effectiveness of a universal parenting skills programme in deprived communities: multicentre randomised controlled trial. BMJ Open, 2013, 3, e002851.	1.9	33
54	Repeated challenge with prion disease: The risk of infection and impact on incubation period. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10960-10965.	7.1	32

#	Article	IF	CITATIONS
55	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Communications, 2021, 3, fcab242.	3.3	32
56	Comparison of the spending function method and the christmas tree correction for group sequential trials. Journal of Biopharmaceutical Statistics, 1996, 6, 361-373.	0.8	31
57	Statistical design and analysis of pharmacogenetic trials. Statistics in Medicine, 2005, 24, 1495-1508.	1.6	31
58	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases, 2017, 12, 44.	2.7	31
59	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. Statistics in Biopharmaceutical Research, 2020, 12, 461-477.	0.8	31
60	A multi-stage drop-the-losers design for multi-arm clinical trials. Statistical Methods in Medical Research, 2017, 26, 508-524.	1.5	30
61	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet Journal of Rare Diseases, 2018, 13, 186.	2.7	30
62	Randomised controlled trial evaluating the effectiveness and cost-effectiveness of â€~Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years. Health Technology Assessment, 2017, 21, 1-180.	2.8	30
63	Directions for new developments on statistical design and analysis of small population group trials. Orphanet Journal of Rare Diseases, 2016, 11, 78.	2.7	29
64	Dose selection in seamless phase II/III clinical trials based on efficacy and safety. Statistics in Medicine, 2009, 28, 917-936.	1.6	28
65	Optimized adaptive enrichment designs. Statistical Methods in Medical Research, 2019, 28, 2096-2111.	1.5	28
66	Comparison of Bayesian and frequentist group-sequential clinical trial designs. BMC Medical Research Methodology, 2020, 20, 4.	3.1	28
67	RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 687.	1.6	28
68	Evaluating the Quality of Subgroup Analyses in Randomized Controlled Trials of Therapist-Delivered Interventions for Nonspecific Low Back Pain. Spine, 2014, 39, 618-629.	2.0	27
69	Flexible sequential designs for multiâ€arm clinical trials. Statistics in Medicine, 2014, 33, 3269-3279.	1.6	27
70	Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical Journal, 2017, 59, 609-625.	1.0	27
71	Investigating interventions to increase uptake of HIV testing and linkage into care or prevention for male partners of pregnant women in antenatal clinics in Blantyre, Malawi: study protocol for a cluster randomised trial. Trials, 2017, 18, 349.	1.6	27
72	Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. BMC Medical Research Methodology, 2019, 19, 99.	3.1	27

#	Article	IF	CITATIONS
73	Local impact of the English arm of the UK Bowel Cancer Screening Pilot study. British Journal of Surgery, 2008, 95, 1172-1179.	0.3	26
74	A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints. Journal of Biopharmaceutical Statistics, 2015, 25, 170-189.	0.8	26
75	Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection. JAMA - Journal of the American Medical Association, 2016, 315, 1956.	7.4	25
76	Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies. Biometrics, 2003, 59, 402-409.	1.4	24
77	Estimation after subpopulation selection in adaptive seamless trials. Statistics in Medicine, 2015, 34, 2581-2601.	1.6	24
78	Optimizing Trial Designs for Targeted Therapies. PLoS ONE, 2016, 11, e0163726.	2.5	24
79	Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Statistics in Medicine, 2002, 21, 467-480.	1.6	23
80	Bayesian modelling of multivariate quantitative traits using seemingly unrelated regressions. Genetic Epidemiology, 2005, 28, 313-325.	1.3	23
81	Morbidity from diarrhoea, cough and fever among young children in Nigeria. Annals of Tropical Medicine and Parasitology, 2008, 102, 427-445.	1.6	23
82	Reducing animal numbers in the fixed-dose procedure. Human and Experimental Toxicology, 1995, 14, 315-323.	2.2	22
83	Advanced life support cardiac arrest scenario test evaluation. Resuscitation, 2007, 75, 484-490.	3.0	22
84	The effects of a brief intervention to promote walking on Theory of Planned Behavior constructs: A cluster randomized controlled trial in general practice. Patient Education and Counseling, 2015, 98, 651-659.	2.2	22
85	Learning from previous responses in phase I dose-escalation studies. British Journal of Clinical Pharmacology, 2001, 52, 1-7.	2.4	21
86	Health service use in families where children enter public care: a nested case control study using the General Practice Research Database. BMC Health Services Research, 2012, 12, 65.	2.2	21
87	Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R. Biometrical Journal, 2020, 62, 1264-1283.	1.0	21
88	Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study. Medical Decision Making, 2021, 41, 37-50.	2.4	21
89	In â€~big bang' major incidents do triage tools accurately predict clinical priority?: A systematic review of the literature. Injury, 2011, 42, 460-468.	1.7	20
90	Decision-theoretic designs for small trials and pilot studies: A review. Statistical Methods in Medical Research, 2016, 25, 1022-1038.	1.5	20

#	Article	IF	CITATIONS
91	Randomised controlled trial and economic evaluation of the â€~Families for Health' programme to reduce obesity in children. Archives of Disease in Childhood, 2017, 102, 416-426.	1.9	20
92	Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics, 1998, 54, 279-94.	1.4	20
93	Physiotherapy rehabilitation for osteoporotic vertebral fracture—a randomised controlled trial and economic evaluation (PROVE trial). Osteoporosis International, 2020, 31, 277-289.	3.1	19
94	Comments on the Draft Guidance on "Adaptive Design Clinical Trials for Drugs and Biologics―of the U.S. Food and Drug Administration. Journal of Biopharmaceutical Statistics, 2010, 20, 1125-1131.	0.8	18
95	The effect of real-time CPR feedback and post event debriefing on patient and processes focused outcomes: A cohort study: trial protocol. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2011, 19, 58.	2.6	18
96	Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial. Trials, 2014, 15, 22.	1.6	18
97	Performance characteristics of five triage tools for major incidents involving traumatic injuries to children. Injury, 2016, 47, 988-992.	1.7	18
98	Dataâ€driven treatment selection for seamless phase II/III trials incorporating earlyâ€outcome data. Pharmaceutical Statistics, 2014, 13, 238-246.	1.3	17
99	Can We Convert Between Outcome Measures of Disability for Chronic Low Back Pain?. Spine, 2015, 40, 734-739.	2.0	17
100	Exact sequential tests for single samples of discrete responses using spending functions. Statistics in Medicine, 2000, 19, 3051-3064.	1.6	16
101	A hierarchical Bayesian model for predicting the functional consequences of amino-acid polymorphisms. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 191-206.	1.0	16
102	Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17, 214-230.	1.3	16
103	Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs. Statistics in Medicine, 2006, 25, 3081-3092.	1.6	15
104	Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine, 2009, 28, 1321-1338.	1.6	15
105	An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis, 2012, 56, 1150-1160.	1.2	15
106	Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer, 2014, 110, 1950-1957.	6.4	15
107	A recursive partitioning approach for subgroup identification in individual patient data metaâ€analysis. Statistics in Medicine, 2018, 37, 1550-1561.	1.6	15
108	Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials. Biometrika, 2018, 105, 495-501.	2.4	15

#	Article	IF	CITATIONS
109	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials, 2021, 22, 203.	1.6	15
110	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. Health Technology Assessment, 2019, 23, 1-88.	2.8	15
111	A parametric multistate model for the analysis of carcinogenicity experiments. Lifetime Data Analysis, 1995, 1, 327-346.	0.9	14
112	Simple tests for the external validation of mortality prediction scores. Statistics in Medicine, 2009, 28, 377-388.	1.6	13
113	A cluster randomised controlled trial of the efficacy of a brief walking intervention delivered in primary care: Study protocol. BMC Family Practice, 2011, 12, 56.	2.9	13
114	Planning multiâ€arm screening studies within the context of a drug development program. Statistics in Medicine, 2013, 32, 3424-3435.	1.6	13
115	Flexible selection of a single treatment incorporating shortâ€ŧerm endpoint information in a phase II/III clinical trial. Statistics in Medicine, 2015, 34, 3104-3115.	1.6	13
116	To add or not to add a new treatment arm to a multiarm study: A decisionâ€ŧheoretic framework. Statistics in Medicine, 2019, 38, 3305-3321.	1.6	13
117	Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT. Health Technology Assessment, 2019, 23, 1-318.	2.8	13
118	Evaluating the relationship between moral values and vaccine hesitancy in Great Britain during the COVID-19 pandemic: A cross-sectional survey. Social Science and Medicine, 2022, 308, 115218.	3.8	13
119	Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology. Biometrics, 2001, 57, 1089-1095.	1.4	12
120	Statistical evaluation of the Fixed Concentration Procedure for acute inhalation toxicity assessment. Human and Experimental Toxicology, 2003, 22, 575-585.	2.2	12
121	Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials. Journal of Biopharmaceutical Statistics, 2011, 21, 787-801.	0.8	12
122	A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity. Human and Experimental Toxicology, 2011, 30, 217-238.	2.2	12
123	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. BMC Medical Research Methodology, 2018, 18, 20.	3.1	12
124	An Alternative Approach to the Analysis of Animal Carcinogenicity Studies. Regulatory Toxicology and Pharmacology, 1996, 23, 244-248.	2.7	11
125	Statistical evaluation of the revised fixed-dose procedure. Human and Experimental Toxicology, 2002, 21, 183-196.	2.2	11
126	A study of the efficacy and cost-effectiveness of MRSA screening and monitoring on surgical wards using a new, rapid molecular test (EMMS). BMC Health Services Research, 2007, 7, 160.	2.2	11

#	Article	IF	CITATIONS
127	Measuring the impact and costs of a universal group based parenting programme: protocol and implementation of a trial. BMC Public Health, 2010, 10, 364.	2.9	11
128	A new sighting study for the fixed concentration procedure to allow for gender differences. Human and Experimental Toxicology, 2011, 30, 239-249.	2.2	11
129	Utilizing Rapid Multiple-Locus Variable-Number Tandem-Repeat Analysis Typing To Aid Control of Hospital-Acquired Clostridium difficile Infection: a Multicenter Study. Journal of Clinical Microbiology, 2012, 50, 3244-3248.	3.9	11
130	A comparison of methods for constructing confidence intervals after phase II/III clinical trials. Biometrical Journal, 2014, 56, 107-128.	1.0	11
131	Point and interval estimation in twoâ€stage adaptive designs with time to event data and biomarkerâ€driven subpopulation selection. Statistics in Medicine, 2020, 39, 2568-2586.	1.6	11
132	Protocol for a randomised controlled trial of Subacromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery (START:REACTS). BMJ Open, 2020, 10, e036829.	1.9	11
133	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.7	11
134	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open, 2022, 12, e064173.	1.9	10
135	A Statistical Evaluation of the Fixed Dose Procedure. ATLA Alternatives To Laboratory Animals, 2004, 32, 13-21.	1.0	9
136	Statistical evaluation of an acute dermal toxicity test using the dermal fixed dose procedure. Human and Experimental Toxicology, 2004, 23, 405-412.	2.2	9
137	Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods. Statistics in Medicine, 2012, 31, 2068-2085.	1.6	9
138	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases, 2016, 11, 16.	2.7	9
139	An evaluation of the fixed concentration procedure for assessment of acute inhalation toxicity. Regulatory Toxicology and Pharmacology, 2018, 94, 22-32.	2.7	9
140	An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears. Trials, 2019, 20, 694.	1.6	9
141	Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial. Trials, 2020, 21, 84.	1.6	9
142	Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 1022.	2.6	9
143	Facet joint injections for people with persistent non-specific low back pain (Facet Injection Study): a feasibility study for a randomised controlled trial. Health Technology Assessment, 2017, 21, 1-184.	2.8	9
144	Identifying back pain subgroups: developing and applying approaches using individual patient data collected within clinical trials. Programme Grants for Applied Research, 2016, 4, 1-278.	1.0	9

#	Article	IF	CITATIONS
145	The fixed-dose procedure and the acute-toxic-class method: a mathematical comparison. Human and Experimental Toxicology, 1995, 14, 974-990.	2.2	8
146	A cluster randomized controlled trial of the effectiveness and cost-effectiveness of Intermediate Care Clinics for Diabetes (ICCD): study protocol for a randomized controlled trial. Trials, 2012, 13, 164.	1.6	8
147	Optimal adaptive designs for acute oral toxicity assessment. Journal of Statistical Planning and Inference, 2006, 136, 1781-1799.	0.6	7
148	Evaluation of the effectiveness and cost-effectiveness of Families for Health V2 for the treatment of childhood obesity: study protocol for a randomized controlled trial. Trials, 2013, 14, 81.	1.6	7
149	Changing case Order to Optimise patterns of Performance in mammography Screening (CO-OPS): study protocol for a randomized controlled trial. Trials, 2014, 15, 17.	1.6	7
150	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine, 2018, 157, 163-177.	4.7	7
151	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. Journal of Neurology, 2018, 265, 1795-1802.	3.6	7
152	Point estimation following twoâ€stage adaptive threshold enrichment clinical trials. Statistics in Medicine, 2018, 37, 3179-3196.	1.6	7
153	Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study. Medical Decision Making, 2021, 41, 476-484.	2.4	7
154	Interim analyses in clinical trials. British Journal of Clinical Pharmacology, 2001, 51, 393-393.	2.4	6
155	Opportunities for Reduction in Acute Toxicity Testing via Improved Design. ATLA Alternatives To Laboratory Animals, 2004, 32, 73-80.	1.0	6
156	Software tools for implementing simulation studies in adaptive seamless designs: introducing R package ASD. Trials, 2011, 12, .	1.6	6
157	Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations. Biometrical Journal, 2017, 59, 344-357.	1.0	6
158	Adaptive enrichment designs with a continuous biomarker. Biometrics, 2023, 79, 9-19.	1.4	6
159	Estimating numbers of infectious units from serial dilution assays. Journal of the Royal Statistical Society Series C: Applied Statistics, 2006, 55, 15-30.	1.0	5
160	Sequentially testing for a gene–drug interaction in a genomewide analysis. Statistics in Medicine, 2008, 27, 2022-2034.	1.6	5
161	Designing a series of decisionâ€ŧheoretic phase II trials in a small population. Statistics in Medicine, 2012, 31, 4337-4351.	1.6	5
162	Facet-joint injections for people with persistent non-specific low back pain (FIS): study protocol for a randomised controlled feasibility trial. Trials, 2015, 16, 588.	1.6	5

#	Article	IF	CITATIONS
163	Approximately optimal designs for phase II clinical studies. Journal of Biopharmaceutical Statistics, 1998, 8, 469-487.	0.8	4
164	Modified Weibull multi-state models for the analysis of animal carcinogenicity data. Environmental and Ecological Statistics, 2000, 7, 117-133.	3.5	4
165	Including a time-of-year effect in the analysis of a matched case-control study. Statistics in Medicine, 2004, 23, 3193-3207.	1.6	4
166	A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies. Statistics in Medicine, 2012, 31, 253-268.	1.6	4
167	An alternative method to analyse the biomarkerâ€strategy design. Statistics in Medicine, 2018, 37, 4636-4651.	1.6	4
168	Identification of subgroup effect with an individual participant data meta-analysis of randomised controlled trials of three different types of therapist-delivered care in low back pain. BMC Musculoskeletal Disorders, 2021, 22, 191.	1.9	4
169	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). BMJ Open, 2022, 12, e058050.	1.9	4
170	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. Neurology, 2022, 98, 754-764.	1.1	4
171	Decisionâ€ŧheoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate betaâ€binomial distribution. Biometrical Journal, 2018, 60, 232-245.	1.0	3
172	Statistical Methods for Combining Clinical Trial Phases II And III. , 2007, , 401-417.		3
173	Two-stage designs for phase II cancer trials with ordinal responses. Contemporary Clinical Trials, 2008, 29, 896-904.	1.8	2
174	Estimating the magnitude of carcinogenic effects in long-term animal studies. Human and Experimental Toxicology, 1995, 14, 643-653.	2.2	1
175	Improving the Efficiency of Fixed-Dose Procedures for the Assessment of Acute Oral Toxicity. Drug Information Journal, 1997, 31, 369-385.	0.5	1
176	An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information. Trials, 2011, 12, .	1.6	1
177	Adaptive Multivariate Global Testing. Journal of the American Statistical Association, 2014, 109, 613-623.	3.1	1
178	Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations. Pharmacoeconomics, 2022, 40, 109-120.	3.3	1
179	Development of a model to demonstrate the impact of National Institute of Health and Care Excellence costâ€effectiveness assessment on health utility for targeted medicines. Health Economics (United Kingdom), 2021, 31, 417.	1.7	1
180	Phase II Clinical Trials. , 0, , 15-31.		0

#	Article	IF	CITATIONS
181	Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drugâ€development programme. Pharmaceutical Statistics, 2009, 8, 287-300.	1.3	0
182	Patterns of health service use in families where children enter public care: a nested case-control study using the general practice research database. Archives of Disease in Childhood, 2010, 95, A6.1-A6.	1.9	0
183	The effect of the 2010 resuscitation guidelines on CPR quality: An observational study. Resuscitation, 2013, 84, S24.	3.0	0
184	Using the NIHR Research Design Service. Paediatrics and Child Health (United Kingdom), 2014, 24, 572-573.	0.4	0
185	How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?. BMC Infectious Diseases, 2014, 14, 154.	2.9	0
186	Editorial for the <i>Biometrical Journal</i> Special Issue ISCB 2016. Biometrical Journal, 2018, 60, 231-231.	1.0	0
187	Efficiency of Adaptive Designs. , 2010, , 25-1-25-16.		0
188	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study Journal of Clinical Oncology, 2012, 30, TPS665-TPS665.	1.6	0
189	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter tests Journal of Clinical Oncology, 2013, 31, TPS656-TPS656.	1.6	0
190	Rejoinder to discussion on "Adaptive enrichment designs with a continuous biomarker― Biometrics, 2023, 79, 36-38.	1.4	0
191	The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens. Open Forum Infectious Diseases, 0, , .	0.9	0